Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19.

ABSTRACT: Low levels and function of natural killer (NK) cells are associated with increased coronavirus disease 2019 (COVID-19) severity. NK cell immunotherapy may improve immune function to reduce infection severity. We conducted a first-in-human, open-label, phase 1, dose-escalating (100 × 10⁶, 300 × 10⁶, or 900 × 10⁶ cells) study of a single dose of DVX201, a cord-blood-derived allogeneic NK cell therapy, in hospitalized patients with COVID-19. Participants were followed for 28 days. The maximum allowed steroid dose for eligibility was up to 0.5 mg/kg prednisone (or equivalent) daily. We enrolled nine participants, 3 per dose level. Eight participants had ≥1 comorbidity associated with increased COVID-19 severity, three of whom had a hematologic malignancy. Infus

SUBMITTER: Liu WL 

PROVIDER: S-EPMC11609367 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature